Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

The purpose of this study is to allow continued access to opnurasib (JDQ443) to participants who are benefitting from treatment with opnurasib as a single agent or in combination with other study treatments in pre-defined Novartis-sponsored opnurasib studies and to continue to assess safety in these participants.

Trial Details

NCT ID

NCT07468071

Phase

PHASE1 / PHASE2

Sponsor

Novartis Pharmaceuticals

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Opnurasib
TNO155
trametinib
cetuximab
tislelizumab

Locations (sample)

Sint-Niklaas, Oost Vlaanderen, Belgium|51.16509,4.1437
Montreal, Quebec, Canada|45.50884,-73.58781
Guangzhou, Guangdong, China|23.11667,113.25
Kashiwa, Chiba, Japan|35.86224,139.97732
Koto Ku, Tokyo, Japan

Key Eligibility Criteria

Participant is currently enrolled in a pre-defined Novartis-sponsored study and is receiving opnurasib as single agent or in combination with other…
Participant has received at least 6 cycles of opnurasib in a parent study.
Participant is currently deriving clinical benefit from the study treatment, as determined by the Investigator.
Participants currently receiving treatment in one of the KontRASt studies, including those who have not experienced disease progression or who are …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →